SEC Form 4 · accession 0001209191-19-017236
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kare Schultz
Officer — President and CEO · Director
Period of report
Mar 4, 2019
Accepted (ET)
Mar 6, 2019 · 7:28 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1,F2,F3 | — | Mar 4, 2019 | A | 179,104 | A | — | — | Ordinary Shares | 179,104 | 179,104 | D |
Explanation of responses
- F1Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F2Restricted share units were granted on March 4, 2019, with 59,701 vesting on each of March 4, 2021 and March 4, 2022 and 59,702 vesting on March 4, 2023.
- F3The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.